The Therapeutic Goods Administration fined Mundipharma AU$302,400 while also serving it 24 infringement notices. The claims in question dealt with the drug’s effectiveness managing chronic non-cancer pain. The company has since removed the flagged language.
Estimated reading time: 0 minutes, 20 seconds
Australian Regulators Target Opioid Company for Misleading Claims
- Saturday, Jan 04 2020
- Written by CMO Tech News Staff